Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration

NCT01134055 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01134055
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01134055 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
June 1, 2010
Completion date
October 1, 2012
Enrollment
510 (actual)
Sites
77

Conditions

As the registry lists them; a condition with its own page is linked.

macular degeneration